Central serous chorioretinopathy secondary to intramuscular testosterone therapy

M. Lockhart,M. Ali,M. Mustafa,W. Tormey,S. Sreenan,A. Saaed,J. H. McDermott

IRISH JOURNAL OF MEDICAL SCIENCE（2022）

引用 0|浏览0

暂无评分

摘要

Blurred vision in patients treated with testosterone replacement therapy (TRT) should prompt an ophthalmology review. The potential for reduced risk of central serous chorioretinopathy (CSR) with daily transdermal testosterone remains a matter of conjecture. CSR is a rare potential side effect of TRT.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要